Population
Women enrolled in the Tranexamic Acid for Preventing Postpartum Hemorrhage Following a Vaginal Delivery (TRAAP) trial (n= 3836).
Intervention
Tranexamic acid (TXA), (n= 1918).
Comparison
Placebo (n= 1918).
Outcome
The average total costs in the TXA and control groups were €2,278 ±388 and €2,288 ±409 per woman respectively. In women with postpartum hemorrhage of at least 500 ml (trial primary endpoint), costs were €2,359±354 and €2,409±525); for provider-assessed clinically significant postpartum hemorrhage and postpartum hemorrhage of at least 1000 ml, costs were respectively €2,316±347 vs. €2,381±521 and €2,321±318 vs. €2,411±590 in the tranexamic and placebo groups, respectively. The probabilistic sensitivity analysis showed that the use of TXA had a 65-73% % probability of being cost saving and outcome improving.